Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1522 participants
INTERVENTIONAL
2001-05-31
2005-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Free study-related medical care provided.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alfuzosin (SL770499)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* daytime or nighttime urinary frequency
* urgent feeling to urinate
* difficulty starting urinary stream
* interruption of urinary stream
* feeling of incomplete urination
* Has not had a previous episode of acute urinary retention
* Has not been diagnosed with prostate cancer
* Has not had previous prostate surgery
* Is not an insulin-dependent diabetic
55 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
sanofi-aventis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ICD CSD
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Affiliated Research Center, Inc
Huntsville, Alabama, United States
San Diego Urology Center
La Mesa, California, United States
San Bernardino Urology Associates
San Bernardino, California, United States
San Diego Urological Medical Group
San Diego, California, United States
Pacific Clinical Research
Santa Monica, California, United States
Urology Research Options
Aurora, Colorado, United States
Connecticut Clinical Research Center
Waterbury, Connecticut, United States
South Florida Medical Research
Aventura, Florida, United States
Tampa Bay Medical Research, Inc.
Clearwater, Florida, United States
Advanced Research Institute
New Port Richey, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
Renstar Medical Research
Plantation, Florida, United States
Urology Associates
Marietta, Georgia, United States
Northwestern Center for Clinical Research
Chicago, Illinois, United States
Welborn Clinic
Evansville, Indiana, United States
Northeast Indiana Research
Fort Wayne, Indiana, United States
Urology of Indiana, LLC
Indianapolis, Indiana, United States
Maryland Prostate Cancer
Baltimore, Maryland, United States
Maryland Urology Association
Towson, Maryland, United States
Newton Wellesley Urology
Newton, Massachusetts, United States
Lakeside Urology, P.C.
Saint Joseph, Michigan, United States
Se Urology Network
Southaven, Mississippi, United States
Weill Cornell Medical Center
New York, New York, United States
Advanced Clinical Trials
Eugene, Oregon, United States
Albert Einstein Medical Center
Philadelphia, Pennsylvania, United States
Center for Urologic Care
West Reading, Pennsylvania, United States
Matrix Research
Greenville, South Carolina, United States
Ut Medical Group, Inc.
Memphis, Tennessee, United States
Murfreesboro Medical Center
Murfreesboro, Tennessee, United States
nTouch Research Corporation
Dallas, Texas, United States
Urology Consultants, P.A.
San Antonio, Texas, United States
Urology Associates
Fredericksburg, Virginia, United States
Jeffrey Frankel
Seattle, Washington, United States
University of Wisconsin Hospital & Clinics
Madison, Wisconsin, United States
Midwest Research Specialists, LLC
Milwaukee, Wisconsin, United States
Sanofi-aventis Administrative Office
Macquarie Park, , Australia
Sanofi-aventis Administrative Office
Sofia, , Bulgaria
Sanofi-aventis Administrative Office
Laval, , Canada
Sanofi-aventis Administrative Office
Hørsholm, , Denmark
Sanofi-aventis Administrative Office
Helsinki, , Finland
Sanofi-aventis Administrative Office
Athens, , Greece
Sanofi-aventis Administrative Office
Budapest, , Hungary
Edith Wolfson Hospital
Holon, , Israel
Sapir Med. Center - Meir General Hospital
Kfar Saba, , Israel
Rabin Medical Center-Golda Campus
Petah Tikvah, , Israel
Sourasky Med. Center-Ichilov Hospital
Tel Aviv, , Israel
Sanofi-aventis Administrative Office
Gouda, , Netherlands
Sanofi-aventis Administrative Office
Lysaker, , Norway
Sanofi-aventis Administrative Office
Warsaw, , Poland
Sanofi-aventis Administrative Office
Porto Salvo, , Portugal
Sanofi-aventis Administrative Office
Bucharest, , Romania
Sanofi-aventis Administrative Office
Midrand, , South Africa
Sanofi-aventis Administrative Office
Barcelona, , Spain
Sanofi-aventis Administrative Office
Bromma, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int. 2006 Apr;97(4):734-41. doi: 10.1111/j.1464-410X.2006.06110.x.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SL770499
Identifier Type: -
Identifier Source: secondary_id
EFC4485
Identifier Type: -
Identifier Source: org_study_id